{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:44:55Z","timestamp":1785300295039,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.modpat.2024.100561","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:11:59Z","timestamp":1720656719000},"page":"100561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma"],"prefix":"10.1016","volume":"37","author":[{"given":"Anna","family":"Cali\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7881-8767","authenticated-orcid":false,"given":"Stefano","family":"Marletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Stefanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Marcolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rotellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vicentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pedron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo M.","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-7274","authenticated-orcid":false,"given":"Guido","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2024.100561_bib1","series-title":"Urinary and Male Genital Tumours","year":"2022"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib2","first-page":"23","article-title":"WHO 2022 classification of kidney tumors: what is relevant? An update and future novelties for the pathologist","volume":"115","author":"Cali\u00f2","year":"2022","journal-title":"Pathologica"},{"issue":"7","key":"10.1016\/j.modpat.2024.100561_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2024.100561_bib4","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2024.100561_bib5","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","article-title":"A\u00a0clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients","volume":"44","author":"Lau","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.modpat.2024.100561_bib7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000719","article-title":"Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma","volume":"40","author":"Smith","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2024.100561_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41379-018-0017-7","volume":"31","author":"Muller","year":"2018","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2024.100561_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncy.22071","article-title":"Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: findings from cytologic and limited biopsy samples","volume":"126","author":"Shyu","year":"2018","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2171672","article-title":"Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma","volume":"19","author":"Bersanelli","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.modpat.2024.100561_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.anndiagpath.2017.04.007","article-title":"Programmed death-1 (PD-1) receptor\/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma","volume":"29","author":"Alaghehbandan","year":"2017","journal-title":"Ann Diagn Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2024.100561_bib12","first-page":"3596","article-title":"Determination of the expression of PD-L1 in the morphologic spectrum of renal cell carcinoma","volume":"11","author":"Walter","year":"2020","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.modpat.2024.100561_bib13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3332\/ecancer.2022.1404","article-title":"Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib","volume":"16","author":"Tomar","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.modpat.2024.100561_bib14","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/his.13183","article-title":"A\u00a0distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma","volume":"71","author":"Smith","year":"2017","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.modpat.2024.100561_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","article-title":"Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes","volume":"53","author":"Takahara","year":"2021","journal-title":"Pathology"},{"issue":"7","key":"10.1016\/j.modpat.2024.100561_bib18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.humpath.2012.11.015","article-title":"Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis","volume":"44","author":"Al-Hussain","year":"2013","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100561_bib19","doi-asserted-by":"crossref","DOI":"10.4322\/acr.2020.159","article-title":"Benign multicystic peritoneal mesothelioma: literature review and update","volume":"10","author":"Chand","year":"2020","journal-title":"Autops Case Rep"},{"issue":"3","key":"10.1016\/j.modpat.2024.100561_bib20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/cancers15030662","article-title":"Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma","volume":"15","author":"Kusamura","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.modpat.2024.100561_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2024.100561_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151599","article-title":"Fumarate hydratase-deficient renal cell carcinoma: a clinicopathological study of seven cases including hereditary and sporadic forms","volume":"49","author":"Kuroda","year":"2020","journal-title":"Ann Diagn Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100561_bib23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/PAS.0000000000000127","article-title":"Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma","volume":"38","author":"Udager","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13073-023-01182-7","article-title":"Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma","volume":"15","author":"Liang","year":"2023","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.modpat.2024.100561_bib25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.modpat.2024.100561_bib27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cancers11081110","article-title":"MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge","volume":"11","author":"Cali\u00f2","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.modpat.2024.100561_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/modpathol.2017.144","article-title":"t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa\/epithelioid angiomyolipoma","volume":"31","author":"Cali\u00f2","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100561_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/his.14683","article-title":"Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression","volume":"81","author":"Kammerer-Jacquet","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2010.01486.x","article-title":"Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis","volume":"79","author":"Smit","year":"2011","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.modpat.2024.100561_bib31","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1210\/jc.2004-2377","article-title":"Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical Cushing syndrome: a clinical and molecular genetic investigation","volume":"90","author":"Matyakhina","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.modpat.2024.100561_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/PAT.0b013e328353bf5a","article-title":"Bilateral ovarian steroid cell tumours and massive macronodular adrenocortical disease in a patient with hereditary leiomyomatosis and renal cell cancer syndrome","volume":"44","author":"Arora","year":"2012","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.modpat.2024.100561_bib33","first-page":"430","article-title":"Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer","volume":"189","author":"Shuch","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.modpat.2024.100561_bib34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/PAP.0000000000000321","article-title":"Low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma: an update on biologic potential, morphologic spectrum, and differential diagnosis with other low-grade oncocytic tumors","volume":"28","author":"Hamza","year":"2021","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100561_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/10668969211026241","article-title":"Low-grade fumarate hydratase-deficient renal cell carcinoma in a 30-year-old female","volume":"30","author":"Wyvekens","year":"2022","journal-title":"Int J Surg Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100561_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/his.13865","article-title":"Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?","volume":"75","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.modpat.2024.100561_bib37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/PAS.0000000000001457","article-title":"Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study","volume":"44","author":"Tjota","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/PAS.0000000000000508","article-title":"Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2024.100561_bib39","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e318227e7f4","article-title":"Renal tumors associated with germline SDHB mutation show distinctive morphology","volume":"35","author":"Gill","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100561_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PAP.0000000000000340","article-title":"Response to the letter to the editor entitled \u201cDo we have sufficient evidence to define prognosis for \u2018low-grade\u2019 fumarate hydratase-deficient renal cell carcinoma?\u201d","volume":"29","author":"Smith","year":"2022","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100561_bib41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PAP.0000000000000335","article-title":"Do we have sufficient evidence to define prognosis for \u201clow-grade\u201d fumarate hydratase-deficient renal cell carcinoma?","volume":"29","author":"Gupta","year":"2022","journal-title":"Adv Anat Pathol"},{"issue":"14","key":"10.1016\/j.modpat.2024.100561_bib42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.modpat.2024.100561_bib43","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00428-023-03549-y","article-title":"STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinoma","volume":"483","author":"Marletta","year":"2023","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12894-019-0484-2","article-title":"Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures","volume":"19","author":"Park","year":"2019","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100561_bib46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients","volume":"51","author":"Choi","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.modpat.2024.100561_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tcb.2020.09.010","article-title":"Metabolic coordination of cell fate by \u03b1-ketoglutarate-dependent dioxygenases","volume":"31","author":"Baksh","year":"2021","journal-title":"Trends Cell Biol"},{"issue":"36","key":"10.1016\/j.modpat.2024.100561_bib48","doi-asserted-by":"crossref","first-page":"25903","DOI":"10.1074\/jbc.M603414200","article-title":"Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression","volume":"281","author":"Peng","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"13","key":"10.1016\/j.modpat.2024.100561_bib49","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2024.100561_bib50","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224001418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224001418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T13:49:24Z","timestamp":1726667364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395224001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0893395224001418"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100561","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100561"}}